ArticleScientific reports2025
Ferroptosis-related gene analysis revealing novel biomarkers and therapeutic targets in diffuse large B-cell lymphoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Diffuse large B-cell lymphoma (DLBCL) is an aggressive, heterogeneous non-Hodgkin lymphoma with high relapse rates and drug resistance, which necessitates novel biomarkers. This study aimed to fill a research gap by investigating the function of ferroptosis-an iron-dependent form of programmed cell death-in DLBCL, an area that remains inadequately explored. Employing a comprehensive bioinformatics framework, we analyzed ferroptosis-related genes in The Cancer Genome Atlas-DLBCL dataset using consensus clustering and differential expression, somatic mutation, copy number variation (CNV), gene ontology and pathway enrichment, and immune infiltration analyses. Our analysis identified two DLBCL subtypes, revealing 912 differentially expressed genes, including 24 ferroptosis-related differentially expressed genes (FRDEGs). Enrichment analyses indicated that these genes are involved in crucial biological pathways, including the lipoxygenase pathway and inflammatory regulation, while immune infiltration assessment highlighted significant correlations with specific immune cell types, particularly the positive correlation of IDO1 with M1 macrophages and the negative correlation of IFNG with memory B cells. Further, we established a prognostic risk model incorporating CDKN1A, KLF2, and IFNG that holds promise for predicting patient outcomes. These findings demonstrate that ferroptosis regulates DLBCL progression and identify potential biomarkers/therapeutic targets requiring validation to develop new therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.